Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Imaging of glutamate in the spinal cord using GluCEST.
Structural features of the Nogo receptor signaling complexes at the neuron/myelin interface.
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.
Missing links in multiple sclerosis etiology. A working connecting hypothesis.
Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology.
Open-ring enhancement in pseudotumoral multiple sclerosis: important radiological aspect.
[Disruption of the blood-brain barrier in inflammatory neurological diseases].
Imaging resting state brain function in multiple sclerosis.
Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.
Anti-drug antibodies: B-cell Immunity against therapy.
Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Perceived changes and minimum clinically important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS).
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Psychiatric disorders revealing multiple sclerosis after 20 years of evolvement.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients.
Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture.
Deep brain stimulation of the ventral intermediate nucleus of the thalamus for tremor in patients with multiple sclerosis.
Oligoclonal bands in the cerebrospinal fluid and increased brain atrophy in early stages of relapsing-remitting multiple sclerosis.
Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge.
Never-resting microglia: physiological roles in the healthy brain and pathological implications.
Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial.
Fingolimod (Gilenya) eligibility extended by NHS England
Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012).
Multiple sclerosis: RBPJ identified as an autoantigen in multiple sclerosis.
The effects of identification with a support group on the mental health of people with multiple sclerosis.
Pages
« first
‹ previous
…
277
278
279
280
281
282
283
284
285
…
next ›
last »